152 related articles for article (PubMed ID: 20337582)
1. Therapeutic utility and medicinal chemistry of cathepsin C inhibitors.
Guay D; Beaulieu C; Percival MD
Curr Top Med Chem; 2010; 10(7):708-16. PubMed ID: 20337582
[TBL] [Abstract][Full Text] [Related]
2. Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases.
Guarino C; Hamon Y; Croix C; Lamort AS; Dallet-Choisy S; Marchand-Adam S; Lesner A; Baranek T; Viaud-Massuard MC; Lauritzen C; Pedersen J; Heuzé-Vourc'h N; Si-Tahar M; Fıratlı E; Jenne DE; Gauthier F; Horwitz MS; Borregaard N; Korkmaz B
Biochem Pharmacol; 2017 May; 131():52-67. PubMed ID: 28193451
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of cathepsin C: from pathophysiology to treatment.
Korkmaz B; Caughey GH; Chapple I; Gauthier F; Hirschfeld J; Jenne DE; Kettritz R; Lalmanach G; Lamort AS; Lauritzen C; Łȩgowska M; Lesner A; Marchand-Adam S; McKaig SJ; Moss C; Pedersen J; Roberts H; Schreiber A; Seren S; Thakker NS
Pharmacol Ther; 2018 Oct; 190():202-236. PubMed ID: 29842917
[TBL] [Abstract][Full Text] [Related]
4. Papillon-Lefèvre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans.
Pham CT; Ivanovich JL; Raptis SZ; Zehnbauer B; Ley TJ
J Immunol; 2004 Dec; 173(12):7277-81. PubMed ID: 15585850
[TBL] [Abstract][Full Text] [Related]
5. Design and evaluation of inhibitors for dipeptidyl peptidase I (Cathepsin C).
Kam CM; Götz MG; Koot G; McGuire M; Thiele D; Hudig D; Powers JC
Arch Biochem Biophys; 2004 Jul; 427(2):123-34. PubMed ID: 15196986
[TBL] [Abstract][Full Text] [Related]
6. In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C.
Méthot N; Guay D; Rubin J; Ethier D; Ortega K; Wong S; Normandin D; Beaulieu C; Reddy TJ; Riendeau D; Percival MD
Mol Pharmacol; 2008 Jun; 73(6):1857-65. PubMed ID: 18326050
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
Méthot N; Rubin J; Guay D; Beaulieu C; Ethier D; Reddy TJ; Riendeau D; Percival MD
J Biol Chem; 2007 Jul; 282(29):20836-46. PubMed ID: 17535802
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C.
Korkmaz B; Lesner A; Wysocka M; Gieldon A; Håkansson M; Gauthier F; Logan DT; Jenne DE; Lauritzen C; Pedersen J
Biochem Pharmacol; 2019 Jun; 164():349-367. PubMed ID: 30978322
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin C inhibitors as anti-inflammatory drug discovery: Challenges and opportunities.
Shen XB; Chen X; Zhang ZY; Wu FF; Liu XH
Eur J Med Chem; 2021 Dec; 225():113818. PubMed ID: 34492551
[TBL] [Abstract][Full Text] [Related]
10. The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2.
Mølgaard A; Arnau J; Lauritzen C; Larsen S; Petersen G; Pedersen J
Biochem J; 2007 Feb; 401(3):645-50. PubMed ID: 17020538
[TBL] [Abstract][Full Text] [Related]
11. Chemical mechanism of a cysteine protease, cathepsin C, as revealed by integration of both steady-state and pre-steady-state solvent kinetic isotope effects.
Schneck JL; Villa JP; McDevitt P; McQueney MS; Thrall SH; Meek TD
Biochemistry; 2008 Aug; 47(33):8697-710. PubMed ID: 18656960
[TBL] [Abstract][Full Text] [Related]
12. Addition of thiols to the double bond of dipeptide C-terminal dehydroalanine as a source of new inhibitors of cathepsin C.
Lenartowicz P; Makowski M; Oszywa B; Haremza K; Latajka R; Pawełczak M; Kafarski P
Biochimie; 2017 Aug; 139():46-55. PubMed ID: 28528273
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin C inhibition as a potential treatment strategy in cancer.
Korkmaz B; Lamort AS; Domain R; Beauvillain C; Gieldon A; Yildirim AÖ; Stathopoulos GT; Rhimi M; Jenne DE; Kettritz R
Biochem Pharmacol; 2021 Dec; 194():114803. PubMed ID: 34678221
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin C role in inflammatory gastroenterological, renal, rheumatic, and pulmonary disorders.
Aghdassi AA; Pham C; Zierke L; Mariaule V; Korkmaz B; Rhimi M
Biochimie; 2024 Jan; 216():175-180. PubMed ID: 37758158
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase I: importance of progranzyme activation sequences, other dipeptide sequences, and the N-terminal amino group of synthetic substrates for enzyme activity.
Tran TV; Ellis KA; Kam CM; Hudig D; Powers JC
Arch Biochem Biophys; 2002 Jul; 403(2):160-70. PubMed ID: 12139965
[TBL] [Abstract][Full Text] [Related]
16. The amino-acid substituents of dipeptide substrates of cathepsin C can determine the rate-limiting steps of catalysis.
Rubach JK; Cui G; Schneck JL; Taylor AN; Zhao B; Smallwood A; Nevins N; Wisnoski D; Thrall SH; Meek TD
Biochemistry; 2012 Sep; 51(38):7551-68. PubMed ID: 22928782
[TBL] [Abstract][Full Text] [Related]
17. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
Schirmeister T
J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
[TBL] [Abstract][Full Text] [Related]
18. Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?
Korkmaz B; Lesner A; Marchand-Adam S; Moss C; Jenne DE
J Med Chem; 2020 Nov; 63(22):13258-13265. PubMed ID: 32692176
[TBL] [Abstract][Full Text] [Related]
19. Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
Hou W; Sun H; Ma Y; Liu C; Zhang Z
J Med Chem; 2019 Jun; 62(12):5901-5919. PubMed ID: 31145622
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of cathepsin C (dipeptidyl peptidase I).
Laine DI; Busch-Petersen J
Expert Opin Ther Pat; 2010 Apr; 20(4):497-506. PubMed ID: 20205619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
